AS 201
Alternative Names: AS-201Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator AcuraStem
- Class Antidementias; Small molecules
- Mechanism of Action PIKFYVE protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Amyotrophic lateral sclerosis; Dementia
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Frontotemporal dementia
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
- 28 Oct 2024 No recent reports of development identified for preclinical development in Frontotemporal dementia in USA
- 24 Sep 2020 AS 201 is available for licensing as of 24 Sep 2020. https://acurastem.com/contact/contact-us (Acurastem website, September 2020)